Cooperative Agreement 1V1CMS331636

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...

This $189,500 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs aims to determine the extent to which cardiovascular disease (CVD) affects individuals with opioid use disorder (OUD) and how patients, providers, and payers can prevent CVD in this population. The key objectives are to: 1) examine the relationship between OUD and time to major adverse cardiovascular events (MACE), 2) identify barriers and...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...

This 3-year, $11,811,988 Cooperative Agreement awarded by the National Institute on Drug Abuse (NIDA) under CFDA 93.279 Drug Use and Addiction Research Programs will support the continued development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing opioid relapse after detoxification. The key objectives are to: 1) submit an Investigational New Drug (IND) application for MCAM to prevent opioid relapse, 2) complete Phase 1 and Phase 1B clinical trials with MCAM, 3)...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to assess the causal impact and equity effects of the New York State Medicaid Value-Based Payment (VBP) policy on outcomes related to opioid use disorder (OUD), including service use, quality, overdose, and healthcare costs. The $1,994,766 award will fund a 1-year research project to be carried out by the Cambridge Public Health Commission, doing...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $326,410 to Berkshire Biomedical Corporation to conduct a two-phased clinical study on the use of a hand-held, automated, personalized oral liquid dispensing system called COPATM for take-home methadone medication management for patients with opioid use disorder (OUD). The Phase I feasibility study will evaluate the functionality and acceptance...

This federal Project Grant award of $421,499 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a comprehensive model and measure of intervention stigma toward medication for opioid use disorder (MOUD). The project will leverage collaborations with subject matter experts to define key domains of intervention stigma, such as beliefs about MOUD pharmacology, prioritization of psychosocial interventions, and...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $702,974 in funding to the Research Foundation of the City University of New York (RFCUNY) to develop and validate a new clinical outcomes assessment (COA) tool for evaluating opioid withdrawal symptoms. The project aims to create a reliable, standardized measure that meets FDA guidelines for qualification, to support the evaluation of...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and pilot test the "Patient Reported Outcome Measures to Individualize Treatment and Improve Retention" (RETAIN) program intervention package. The RETAIN program seeks to capture patient-reported outcome measures (PROMs) in federally-qualified health center (FQHC)-based opioid use disorder (OUD) treatment to improve patient...

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...